Slider Image

Researching therapeutic antibodies against cancer

The antibody discovery research workflow
The antibody discovery research workflow.

In the last 20 years, monoclonal antibody–based treatment for cancer has proven one of the most effective therapeutic strategies for solid tumors, as well as tumors of hematopoietic and lymphoid tissues. Therapeutic antibodies against cancer are used and designed to target cancer surface antigens or to unlock checkpoint inhibitors.

Therapeutic antibody research usually starts with identification and validation of targets for immunotherapy. For subsequent discovery of antibody candidates, B cells are used either for sequencing of B cell receptors (BCRs) or B cell cultivation and binder selection. The final step, antibody functionality is verified using cell-based assays to determine the mode of action and effector function. Often, additional optimization of antibody candidates and further functionality testing is performed to improve specificity, safety, and efficacy.  

Our goal is it to support you at every step of your workflow, to simplify your research, and ensure reproducibility in your data. 

Our therapeutic antibody discovery research solutions support:

  • Target identification through deep phenotyping of the tumor microenvironment by ultra high content imaging with the MACSima™ Imaging Platform
  • Antibody discovery with pure B cell subsets, isolated using MACS® Technology or gently sorted using the MACSQuant® Tyto® Cell Sorter and REAlease® Antibodies
  • Reliable activation and expansion of primary B cells using the B Cell Expansion Kit, human
  • Reproducible functionality screenings, as well as quality controls (QC) for assay read-out by flow cytometry analysis or cytokine profiling
  • Cell-based assays including antibody-dependent cellular cytotoxicity (ADCC) assay, mixed lymphocyte reaction (MLR), immunogenicity screenings, cytokine secretion assays, and many more …

Discover the complete workflow including application data

Seems like you are coming from USA!
Do you want to visit our website in your country?